Sanofi's Matthew Ros Joins Epizyme
Executive Summary
Epizyme Inc. has appointed Matthew Ros chief operating officer (COO). Ros joins the clinical-stage biopharma company from Sanofi, where he was most recently COO, global head of the oncology business unit, overseeing its solid tumour and hematology franchise. Prior to this, he worked within Genzyme’s rare disease business, where he led its second-largest franchise, Pompe disease, as vice president and franchise head. He has also previously served on the board of trustees at CancerCARE.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.